

CS/BSE/NSE/2019-2020
December 3, 2019

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 530239

Scrip Symbol: SUVEN

Dear Sir/Madam,

Sub: Increase in volume

Ref: Your letter No: NSE/CM/Surveillance/8822, dated: December 2, 2019

.....


We write to inform that our company has been notifying NSE & BSE all the information which comes under the purview of Regulation 30 of SEBI (LODR) Regulations, 2015 from time to time.

You are requested to note that during the investors conference call held on 15th November, 2019, post announcement of Q2 Results FY2019-20, our Company informed the investors as well as through investor communication to the stock exchanges on 14th November, 2019 that we are expecting results in next two to three weeks on our Company's Phase 2a study of SUVN-502.

In this connection we have notified through News Release to NSE & BSE on Saturday, (i.e., on 30th November, 2019) about the outcome of Phase 2a studies of our Company's molecule i.e., SUVN-502 immediately upon the information is available with the Company. As such presently we do not have any material event due for notification to the stock exchanges under the said Regulation having a bearing on the price of our Company's scrip.

We request you to take this clarification on your record.

Thanking You,
Yours faithfully,
For **Suven Life Sciences Limited**


K. Hanumantha Rao
Company Secretary

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com